EP1666501A4 - Sugar chain-modified anti-hm1.24 antibody - Google Patents

Sugar chain-modified anti-hm1.24 antibody

Info

Publication number: EP1666501A4
Authority: EP; European Patent Office
Prior art keywords: antibody; sugar chain; modified anti; modified; sugar
Prior art date: 2003-08-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP04771773A

Other languages

German (de)

French (fr)

Other versions

EP1666501A1 (en

Inventor

Masayuki Tsuchiya

Shigeyuki Iijima

Izumi Sugo

Masamichi Sugimoto

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Chugai Pharmaceutical Co Ltd

Original Assignee

Chugai Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-11

Filing date

2004-08-11

Publication date

2008-12-24

2004-08-11 Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd

2006-06-07 Publication of EP1666501A1 publication Critical patent/EP1666501A1/en

2008-12-24 Publication of EP1666501A4 publication Critical patent/EP1666501A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Cell Biology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EP04771773A 2003-08-11 2004-08-11 Sugar chain-modified anti-hm1.24 antibody Withdrawn EP1666501A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2003207165		2003-08-11
PCT/JP2004/011812 WO2005014651A1 (en)	2003-08-11	2004-08-11	Sugar chain-modified anti-hm1.24 antibody

Publications (2)

Publication Number	Publication Date
EP1666501A1 EP1666501A1 (en)	2006-06-07
EP1666501A4 true EP1666501A4 (en)	2008-12-24

Family

ID=34131407

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP04771773A Withdrawn EP1666501A4 (en)	2003-08-11	2004-08-11	Sugar chain-modified anti-hm1.24 antibody

Country Status (4)

Country	Link
US (1)	US20070142627A1 (en)
EP (1)	EP1666501A4 (en)
JP (1)	JPWO2005014651A1 (en)
WO (1)	WO2005014651A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2807767B1 (en) *	2000-04-12	2005-01-14	Lab Francais Du Fractionnement	MONOCLONAL ANTIBODIES ANTI-D
US20080219974A1 (en) *	2002-03-01	2008-09-11	Bernett Matthew J	Optimized antibodies that target hm1.24
JPWO2006067847A1 (en)	2004-12-22	2008-06-12	中外製薬株式会社	Antibody production method using cells in which fucose transporter function is inhibited
WO2006089231A2 (en) *	2005-02-18	2006-08-24	Medarex, Inc.	Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
WO2006089232A2 (en)	2005-02-18	2006-08-24	Medarex, Inc.	Monoclonal antibodies against cd30 lacking fucosyl residues
US20080014203A1 (en) *	2006-04-11	2008-01-17	Silke Hansen	Antibodies against insulin-like growth factor I receptor and uses thereof
CA2660795C (en)	2006-09-18	2014-11-18	Xencor, Inc.	Optimized antibodies that target hm1.24
US10199581B2 (en)	2013-07-01	2019-02-05	Universal Display Corporation	Organic electroluminescent materials and devices
US11108000B2 (en)	2014-08-07	2021-08-31	Unniversal Display Corporation	Organic electroluminescent materials and devices
CN107619443B (en) *	2016-07-14	2020-08-14	深圳宾德生物技术有限公司	Monoclonal antibody against human and mouse CD317 and preparation method and application thereof
AU2020288499A1 (en)	2019-06-05	2022-01-27	Chugai Seiyaku Kabushiki Kaisha	Antibody cleavage site-binding molecule

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA76934C2 (en)	1996-10-04	2006-10-16	Chugai Pharmaceutical Co Ltd	Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
JP3886238B2 (en) *	1997-02-12	2007-02-28	中外製薬株式会社	Treatment for lymphoid tumors
CA2280875C (en) *	1997-02-12	2005-07-05	Chugai Seiyaku Kabushiki Kaisha	Remedies for lymphocytic tumors
EP0972524A4 (en) *	1997-02-28	2001-03-28	Chugai Pharmaceutical Co Ltd	Lymphocyte activation inhibitors
US20030049676A1 (en) *	1997-09-17	2003-03-13	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU3657899A (en) *	1998-04-20	1999-11-08	James E. Bailey	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ES2571230T3 (en)	1999-04-09	2016-05-24	Kyowa Hakko Kirin Co Ltd	Procedure to control the activity of an immunofunctional molecule
PL218428B1 (en)	2000-10-06	2014-12-31	Kyowa Hakko Kogyo Kk	Cells producing antibody compositions
US6946292B2 (en) *	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
JP2005500018A (en)	2001-04-02	2005-01-06	アイデックファーマスーティカルズコーポレイション	Recombinant antibody coexpressed with GnTIII

2004
- 2004-08-11 JP JP2005513047A patent/JPWO2005014651A1/en active Pending
- 2004-08-11 WO PCT/JP2004/011812 patent/WO2005014651A1/en active Application Filing
- 2004-08-11 US US10/567,856 patent/US20070142627A1/en not_active Abandoned
- 2004-08-11 EP EP04771773A patent/EP1666501A4/en not_active Withdrawn

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
B. M. KUMPEL: "Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers", VOX SANGUINIS, vol. 93, no. 2, 1 August 2007 (2007-08-01), pages 99 - 111, XP055002584, ISSN: 0042-9007, DOI: 10.1111/j.1423-0410.2007.00945.x *
DAVIES J ET AL: "Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII", BIOTECHNOLOGY AND BIOENGINEERING - COMBINATORIAL CHEMISTRY, WILEY, NEW YORK, NY, US, vol. 74, no. 4, 20 August 2001 (2001-08-20), pages 288 - 294, XP002285964 *
MORI K ET AL: "Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies", CYTOTECHNOLOGY, vol. 55, 2007, pages 109 - 114 *
ONO KOICHIRO ET AL: "The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 36, no. 6, 1 April 1999 (1999-04-01), pages 387 - 395, XP002282626, ISSN: 0161-5890 *
OZAKI S ET AL: "Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 93, no. 11, 1 June 1999 (1999-06-01), pages 3922 - 3930, XP002214462, ISSN: 0006-4971 *
See also references of WO2005014651A1 *
SHIELDS R L ET AL: "Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgammaRIII and antibody-dependent cellular toxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 277, no. 30, 26 July 2002 (2002-07-26), pages 26733 - 26740, XP002964542, ISSN: 0021-9258 *
SHINKAWA T ET AL: "The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 278, no. 5, 31 January 2003 (2003-01-31), pages 3466 - 3473, XP002965857, ISSN: 0021-9258 *

Also Published As

Publication number	Publication date
US20070142627A1 (en)	2007-06-21
JPWO2005014651A1 (en)	2006-11-24
EP1666501A1 (en)	2006-06-07
WO2005014651A1 (en)	2005-02-17

Publication	Publication Date	Title
HK1084958A1 (en)	2006-08-11	S. pneumoniae antigens
IL175710A0 (en)	2006-09-05	Anti-mpl antibody
GB0305175D0 (en)	2003-04-09	Navigator 2.0 features
EG25273A (en)	2011-12-04	Substituted dihydroquinazolines.
MXPA03002422A (en)	2004-02-12	Engine.
ZA200400386B (en)	2004-08-19	Attachment element.
EP1666501A4 (en)	2008-12-24	Sugar chain-modified anti-hm1.24 antibody
HK1070239A2 (en)	2005-06-10	Container.
ZA200407185B (en)	2005-06-29	Binding element.
GB0306618D0 (en)	2003-04-30	Antibody
EP1618893A4 (en)	2009-08-12	Sugar intake-ability enhancer
GB0310677D0 (en)	2003-06-11	The beaded g
LU91022B1 (en)	2004-11-10	Sektionaltor.
AU157870S (en)	2005-03-31	Sugar container assembly
GB0315045D0 (en)	2003-07-30	Dual.L
PL114818U1 (en)	2004-11-02	V .03
GB0221662D0 (en)	2002-10-30	The R.G. strip
ZA200408301B (en)	2005-07-06	Spouts.
ZA200502422B (en)	2005-10-04	Sunshades.
AU2961P (en)	2006-01-24	Kalka Triticum turgidum ssp. turgidum
HK1053596A1 (en)	2003-10-31	Closestool cover.
AU2003100553A4 (en)	2003-08-21	The edge
ZA200409600B (en)	2005-07-18	Closure assembly.
TJ391B (en)	2004-10-13	Medicinal-preventive biopreparation subtilben.
GB0307972D0 (en)	2003-05-14	E.b.o.e.s.s

Legal Events

Date	Code	Title	Description
2006-05-05	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2006-06-07	17P	Request for examination filed	Effective date: 20060308
2006-06-07	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
2006-11-15	DAX	Request for extension of the european patent (deleted)
2008-12-24	A4	Supplementary search report drawn up and despatched	Effective date: 20081125
2009-05-13	17Q	First examination report despatched	Effective date: 20090415
2010-06-02	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/30 20060101AFI20100426BHEP Ipc: C12P 21/08 20060101ALI20100426BHEP Ipc: C12N 15/16 20060101ALI20100426BHEP
2011-12-22	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2012-10-05	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2012-11-07	18D	Application deemed to be withdrawn	Effective date: 20120515